Arcellx, Inc. (ACLX)

NMS – Real vaqt narxi. Valyuta: USD

115.07

+115.07 (0.00%)

Yopilishda: Apr 27, 2026, 4:00 PM EDT

28.04.2026

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and.

27.04.2026

Are Medical Stocks Lagging Arcellx (ACLX) This Year?

Here is how Arcellx, Inc. (ACLX) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.

19.03.2026

Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders

NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Kennedy-Wilson Holdings, Inc. (NYSE: KW)'s sale to consortium led by William McMorrow, Chairman and Chief Executive Officer of Kennedy-Wilson, and certain other senior executives of Kennedy-Wilson, together with Fairfax Financial Holdings Limited, for $10.90 per share in cash. If you are a Kennedy-Wilson shareholder, click here to learn more about your rights and options.

18.03.2026

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

As of March 18, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

16.03.2026

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal

Cormorant Asset Management sold 775,000 Arcellx shares in the fourth quarter. The fund's quarter-end position value in Arcellx decreased by $63.63 million, reflecting a complete position sale during the period.

13.03.2026

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Arcellx, Inc. (NasdaqGS: ACLX) to Gilead Sciences, Inc. (NasdaqGS: GILD). Under the terms of the proposed transaction, shareholders of Arcellx will receive $115.00 per share in cash plus one contingent value right of $5.00 per share upon the achievement of certain milestones. KSF is seeking to deter.

04.03.2026

Top 2 Health Care Stocks That May Crash This Quarter

As of March 4, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Videolar

No Data

There is no data to display

Press-relizlar

28.04.2026

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

19.03.2026

Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders

13.03.2026

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

24.02.2026

Arcellx, Inc. (ACLX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Arcellx, Inc. (ACLX)

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

Are Medical Stocks Lagging Arcellx (ACLX) This Year?

Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Top 2 Health Care Stocks That May Crash This Quarter

Videolar

No Data

Press-relizlar

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

Are Medical Stocks Lagging Arcellx (ACLX) This Year?

Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Top 2 Health Care Stocks That May Crash This Quarter

Videolar

No Data

Press-relizlar

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Search stocks

Arcellx, Inc. (ACLX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Arcellx, Inc. (ACLX)

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

Are Medical Stocks Lagging Arcellx (ACLX) This Year?

Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Top 2 Health Care Stocks That May Crash This Quarter

Videolar

No Data

Press-relizlar

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

Are Medical Stocks Lagging Arcellx (ACLX) This Year?

Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Top 2 Health Care Stocks That May Crash This Quarter

Videolar

No Data

Press-relizlar

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX